Naperville, United States
Endotronix, founded in 2007, is a pioneering force at the nexus of Medtech and Digital Health, focused on advancing heart failure care. Their core product, the Cordella solution, leverages pulmonary artery (PA) pressure analytics alongside vital sign data to facilitate proactive management of heart failure directly at home. This innovation enhances patient engagement, mitigates congestion, and notably improves medical outcomes.
Operating out of the United States, Endotronix is a significant player within the Biotechnology, Health Care, IT, and Medical Devices industries. The company's last major capital infusion was a $70.00M Series D round on 14 September 2018. Leading investors in this round included renowned firms such as SV Health Investors, Aperture Venture Partners, and BioVentures Investors, among others.
As a part of Edwards Lifesciences, Endotronix continues its mission encapsulated in its slogan: "Advancing the Treatment of Heart Failure. Together."
